nNOS-mediated protein-protein interactions:promising targets for treating neurological and neuropsychiatric disorders

• 来源期刊: 生物医学研究杂志（英文版）
• 年，卷（期）: 2021,（1）
• 所属期刊栏目: REVIEW ARTICLE
• 页码范围: 1-10
• 页数: 10页
• 分类号: R74
• 语种: 英文

摘要

Neurological and neuropsychiatric disorders are one of the leading causes of disability worldwide and affect the health of billions of people.Nitric oxide (NO),a free gas with multitudinous bioactivities,is mainly produced from the oxidation of L-arginine by neuronal nitric oxide synthase (nNOS) in the brain.Inhibiting nNOS benefits a variety of neurological and neuropsychiatric disorders,including stroke,depression and anxiety disorders,post-traumatic stress disorder,Parkinson's disease,Alzheimer's disease,chronic pain,and drug addiction.Due to critical roles of nNOS in learning and memory and synaptic plasticity,direct inhibition of nNOS may cause severe side effects.Importantly,interactions of several proteins,including post-synaptic density 95 (PSD-95),carboxy-terminal PDZ ligand of nNOS (CAPON) and serotonin transporter (SERT),with the PSD/Disc-large/ZO-1 homologous (PDZ) domain of nNOS have been demonstrated to influence the subcellular distribution and activity of the enzyme in the brain.Therefore,it will be a preferable means to interfere with nNOS-mediated protein-protein interactions (PPIs),which do not lead to undesirable effects.Herein,we summarize the current literatures on nNOS-mediated PPIs involved in neurological and neuropsychiatric disorders,and the discovery of drugs targeting the PPIs,which is expected to provide potential targets for developing novel drugs and new strategy for the treatment of neurological and neuropsychiatric disorders.